A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease

Martin Bauer; Oliver Langer; Peter Dal-Bianco; Rudolf Karch; Martin Brunner; Aiman Abrahim; Rupert Lanzenberger; Andrea Hofmann; Christian Joukhadar; Paolo Carminati; Orlando Ghirardi; Paola Piovesan; Gianluigi Forloni; Mario E. Corrado; Nadège Lods; Robert Dudczak; Eduard Auff; Kurt Kletter; Markus Müller

doi:10.1016/j.clpt.2006.05.007

A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease

Martin Bauer, Oliver Langer, Peter Dal-Bianco, Rudolf Karch, Martin Brunner, Aiman Abrahim, Rupert Lanzenberger, Andrea Hofmann, Christian Joukhadar, Paolo Carminati, Orlando Ghirardi, Paola Piovesan, Gianluigi Forloni, Mario E. Corrado, Nadège Lods, Robert Dudczak, Eduard Auff, Kurt Kletter, Markus Müller

Istituto di Ricerche Farmacologiche "Mario Negri"

Research output: Contribution to journal › Article › peer-review

Abstract

This work describes a microdosing study with an investigational, carbon 11-labeled antiamyloid drug, 1,1′-methylene-di-(2-naphthol) (ST1859), and positron emission tomography (PET) in healthy volunteers (n = 3) and patients with Alzheimer's disease (n = 6). The study aimed to assess the distribution and local tissue pharmacokinetics of the study drug in its target organ, the human brain. Before PET studies were performed in humans, the toxicologic characteristics of ST1859 were investigated by an extended single-dose toxicity study according to guidelines of the Food and Drug Administration and European Medicines Agency, which are relevant for clinical trials with a single microdose. After intravenous bolus injection of 341 ± 21 MBq [¹¹C]ST1859 (containing

Original language	English
Pages (from-to)	216-227
Number of pages	12
Journal	Clinical Pharmacology and Therapeutics
Volume	80
Issue number	3
DOIs	https://doi.org/10.1016/j.clpt.2006.05.007
Publication status	Published - Sep 2006

ASJC Scopus subject areas

Pharmacology

Access to Document

10.1016/j.clpt.2006.05.007

Cite this

Bauer, M., Langer, O., Dal-Bianco, P., Karch, R., Brunner, M., Abrahim, A., Lanzenberger, R., Hofmann, A., Joukhadar, C., Carminati, P., Ghirardi, O., Piovesan, P., Forloni, G., Corrado, M. E., Lods, N., Dudczak, R., Auff, E., Kletter, K., & Müller, M. (2006). A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease. Clinical Pharmacology and Therapeutics, 80(3), 216-227. https://doi.org/10.1016/j.clpt.2006.05.007

Bauer, M, Langer, O, Dal-Bianco, P, Karch, R, Brunner, M, Abrahim, A, Lanzenberger, R, Hofmann, A, Joukhadar, C, Carminati, P, Ghirardi, O, Piovesan, P, Forloni, G, Corrado, ME, Lods, N, Dudczak, R, Auff, E, Kletter, K & Müller, M 2006, 'A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease', Clinical Pharmacology and Therapeutics, vol. 80, no. 3, pp. 216-227. https://doi.org/10.1016/j.clpt.2006.05.007

@article{668d36b836cd4d4bb3cc903a31c7dd4c,

title = "A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease",

abstract = "This work describes a microdosing study with an investigational, carbon 11-labeled antiamyloid drug, 1,1′-methylene-di-(2-naphthol) (ST1859), and positron emission tomography (PET) in healthy volunteers (n = 3) and patients with Alzheimer's disease (n = 6). The study aimed to assess the distribution and local tissue pharmacokinetics of the study drug in its target organ, the human brain. Before PET studies were performed in humans, the toxicologic characteristics of ST1859 were investigated by an extended single-dose toxicity study according to guidelines of the Food and Drug Administration and European Medicines Agency, which are relevant for clinical trials with a single microdose. After intravenous bolus injection of 341 ± 21 MBq [11C]ST1859 (containing ",

author = "Martin Bauer and Oliver Langer and Peter Dal-Bianco and Rudolf Karch and Martin Brunner and Aiman Abrahim and Rupert Lanzenberger and Andrea Hofmann and Christian Joukhadar and Paolo Carminati and Orlando Ghirardi and Paola Piovesan and Gianluigi Forloni and Corrado, {Mario E.} and Nad{\`e}ge Lods and Robert Dudczak and Eduard Auff and Kurt Kletter and Markus M{\"u}ller",

year = "2006",

month = sep,

doi = "10.1016/j.clpt.2006.05.007",

language = "English",

volume = "80",

pages = "216--227",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease

AU - Bauer, Martin

AU - Langer, Oliver

AU - Dal-Bianco, Peter

AU - Karch, Rudolf

AU - Brunner, Martin

AU - Abrahim, Aiman

AU - Lanzenberger, Rupert

AU - Hofmann, Andrea

AU - Joukhadar, Christian

AU - Carminati, Paolo

AU - Ghirardi, Orlando

AU - Piovesan, Paola

AU - Forloni, Gianluigi

AU - Corrado, Mario E.

AU - Lods, Nadège

AU - Dudczak, Robert

AU - Auff, Eduard

AU - Kletter, Kurt

AU - Müller, Markus

PY - 2006/9

Y1 - 2006/9

N2 - This work describes a microdosing study with an investigational, carbon 11-labeled antiamyloid drug, 1,1′-methylene-di-(2-naphthol) (ST1859), and positron emission tomography (PET) in healthy volunteers (n = 3) and patients with Alzheimer's disease (n = 6). The study aimed to assess the distribution and local tissue pharmacokinetics of the study drug in its target organ, the human brain. Before PET studies were performed in humans, the toxicologic characteristics of ST1859 were investigated by an extended single-dose toxicity study according to guidelines of the Food and Drug Administration and European Medicines Agency, which are relevant for clinical trials with a single microdose. After intravenous bolus injection of 341 ± 21 MBq [11C]ST1859 (containing

AB - This work describes a microdosing study with an investigational, carbon 11-labeled antiamyloid drug, 1,1′-methylene-di-(2-naphthol) (ST1859), and positron emission tomography (PET) in healthy volunteers (n = 3) and patients with Alzheimer's disease (n = 6). The study aimed to assess the distribution and local tissue pharmacokinetics of the study drug in its target organ, the human brain. Before PET studies were performed in humans, the toxicologic characteristics of ST1859 were investigated by an extended single-dose toxicity study according to guidelines of the Food and Drug Administration and European Medicines Agency, which are relevant for clinical trials with a single microdose. After intravenous bolus injection of 341 ± 21 MBq [11C]ST1859 (containing

UR - http://www.scopus.com/inward/record.url?scp=33748157070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748157070&partnerID=8YFLogxK

U2 - 10.1016/j.clpt.2006.05.007

DO - 10.1016/j.clpt.2006.05.007

M3 - Article

C2 - 16952488

AN - SCOPUS:33748157070

VL - 80

SP - 216

EP - 227

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 3

ER -

A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this